Regulatory and reimbursement landscape of CGTs
Objective
The aim of this study was to:
- Identify approved CGTs by EMA in France, Germany, Italy, and MHRA in the UK
- Explore the reimbursement landscape of CGTs across four countries including key outcomes of HTA assessments and time to reimbursement (TTR)
- Assess the use of early access schemes for CGTs across scope countries
Complete the form to download the full report.
